Video

Audra Moran on the Ovarian Cancer National Conference

Author(s):

Audra Moran
Conference|Ovarian Cancer National Conference

Audra Moran, CEO & President of the Ovarian Cancer Research Fund Alliance discusses the Ovarian Cancer National Conference.

Audra Moran, CEO & President of the Ovarian Cancer Research Fund Alliance discusses the Ovarian Cancer National Conference. At the conference, survivors have a safe space to connect, can meet and learn from experts and also plan for moving forward.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of woman with text.
Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute.
Kidney Cancer Research Embraces Biology-Driven Precision Approach
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Image of two doctors and text.
Imiage of two doctors with text.
Image of two doctors and text.
Image of patient and doctor.
Related Content
PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer: © stock.adobe.com.
July 24th 2025

Key Immune Cells Linked to Better Kidney Cancer Outcomes

Ashley Chan
PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer; higher CD163-positive TAMs are linked to better outcomes.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Adding casdatifan to Cabometyx showed encouraging activity and in previously treated ccRCC: © stock.adobe.com.
July 23rd 2025

Welireg Plus Cabometyx Shows Tumor Control in Kidney Cancer Trial

Tim Cortese
Adding casdatifan to Cabometyx therapy showed encouraging activity and was generally well tolerated in previously treated clear cell renal cell carcinoma.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase inhibitors in patients kidney cancer: © stock.adobe.com
July 21st 2025

Metastasis-Directed Radiotherapy Shows Improved Kidney Cancer Outcomes

Tim Cortese
Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase inhibitors in patients kidney cancer.
Image of kidney.
July 20th 2025

Welireg Improves Quality-Adjusted Survival Time in Advanced RCC

Russ Conroy
Welireg improved quality-adjusted survival time versus Afinitor in advanced renal cell carcinoma, extending progression-free survival and reducing side effects.